These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 29296138)

  • 1. Beyond new vaccine introduction: the uptake of pneumococcal conjugate vaccine in the African Region.
    Olayinka F; Ewald L; Steinglass R
    Pan Afr Med J; 2017; 27(Suppl 3):3. PubMed ID: 29296138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pneumococcal conjugate vaccine introductions in four sub-Saharan African countries: a cross-country analysis of health systems' impacts.
    Torres-Rueda S; Burchett HE; Griffiths UK; Ongolo-Zogo P; Edengue JM; Kitaw Y; Molla M; Gelmon L; Onyango-Ouma W; Konate M; Mounier-Jack S
    Afr Health Sci; 2015 Sep; 15(3):868-77. PubMed ID: 26957976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants.
    Lin ND; Kleinman K; Chan KA; Yu XJ; France EK; Xu S; Wei F; Mullooly J; Santoli J; Lieu TA;
    BMC Pediatr; 2005 Nov; 5():43. PubMed ID: 16313673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Vaccine Introduction and Childhood Vaccination Timeliness in Two Urban, Informal Settlements in Nairobi, Kenya.
    Janusz CB; Mutua MK; Wagner AL; Boulton ML
    Am J Trop Med Hyg; 2021 May; 105(1):245-253. PubMed ID: 33999852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.
    Madhi SA; Nunes MC
    Hum Vaccin Immunother; 2016; 12(2):314-25. PubMed ID: 26317537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates on state-specific Pneumococcal Conjugate Vaccines (PCV) coverage in the private sector in the year 2012: Evidence from PCV utilization data.
    Farooqui HH; Zodpey S; Chokshi M; Thacker N
    Indian J Public Health; 2016; 60(2):145-9. PubMed ID: 27350710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of New Vaccine Introduction - Worldwide, September 2016.
    Loharikar A; Dumolard L; Chu S; Hyde T; Goodman T; Mantel C
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1136-1140. PubMed ID: 27764083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and timeliness of rotavirus vaccination in Norway: The first year post-introduction.
    Valcarcel Salamanca B; Hagerup-Jenssen ME; Flem E
    Vaccine; 2016 Sep; 34(39):4684-4689. PubMed ID: 27522178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi.
    Williams BA; Kidane T; Chirwa G; Tesfaye N; Prescott MR; Scotney ST; Valle M; Abebe S; Tambuli A; Malewezi B; Mohammed T; Kobayashi E; Wootton E; Wong R; Dosani R; Subramaniam H; Joseph J; Yavuz E; Apple A; Le Tallec Y; Kang'ethe A
    Health Policy Plan; 2016 Jun; 31(5):563-72. PubMed ID: 26856361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of pneumococcal conjugate vaccine on community-acquired pneumonia hospitalizations in children with comorbidity.
    Sterky E; Bennet R; Lindstrand A; Eriksson M; Nilsson A
    Eur J Pediatr; 2017 Mar; 176(3):337-342. PubMed ID: 28070670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
    Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
    Kyaw MH; Jones IG; Campbell H
    Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012.
    Griffin MR; Mitchel E; Moore MR; Whitney CG; Grijalva CG;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(44):995-8. PubMed ID: 25375070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.
    Becker-Dreps S; Amaya E; Liu L; Moreno G; Rocha J; Briceño R; Alemán J; Hudgens MG; Woods CW; Weber DJ
    Pediatr Infect Dis J; 2014 Jun; 33(6):637-42. PubMed ID: 24445827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.